Factor This Power Engineering
Live Events
DTECH® Events
POWERGEN™
INFOCAST Events
Calendar
Webinars
Podcasts
Factor This
This Week in Cleantech
Factor This Policycast
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
POWERGEN™
INFOCAST Events
Podcasts
Factor This
Factor This Policycast
This Week in Cleantech
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rezolute, Inc. - Common Stock (NV)
(NQ:
RZLT
)
4.965
+0.035 (+0.71%)
Streaming Delayed Price
Updated: 2:55 PM EDT, Jul 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rezolute, Inc. - Common Stock (NV)
< Previous
1
2
3
4
5
6
7
Next >
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Analyst Expectations for Rezolute's Future
↗
November 14, 2023
Via
Benzinga
Expert Ratings for Rezolute
↗
September 18, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Rezolute
↗
June 28, 2023
Via
Benzinga
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
↗
December 20, 2023
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL...
Via
Benzinga
Topics
Intellectual Property
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 13, 2023
Plans to report topline data mid-second quarter 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
November 24, 2023
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday...
Via
Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
November 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 17, 2023
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 11, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
↗
October 02, 2023
On Monday, 369 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
September 15, 2023
Via
Benzinga
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
September 14, 2023
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
From
Rezolute, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
September 08, 2023
Via
Benzinga
Rezolute to Participate in Upcoming Investor Conferences in September
September 06, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
↗
July 07, 2023
The Dow Jones closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
June 27, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
June 01, 2023
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare...
Via
Newsfile
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
May 11, 2023
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 23, 2023
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
March 08, 2023
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 10, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
↗
December 19, 2022
On Monday, 297 companies reached new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 16, 2022
Via
Benzinga
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
December 15, 2022
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
November 09, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Present at the Jefferies London Healthcare Conference
November 01, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
